French pharmaceutical giant, Sanofi (NASDAQ:SNY), has forecasted a substantial impact on its third-quarter sales and business earnings per share (EPS) due to currency movements. This prediction is based on foreign exchange fluctuations observed until September 15, as per the company's preliminary estimates released last Friday.
Availability of the Q3 2023 Memorandum for modelling purposes Paris, France – September 22, 2023. Sanofi announced today that its Q3 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/q3-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various
Sanofi is all in on AI and thinks it could help alleviate patent timeline pressures from the Inflation Reduction Act.